SCHEMBL2000699

SCHEMBL2000699

NC(=O)NCC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13999422 0.91 TDP1 (0.83)
SCHEMBL4697448 0.91 TDP1 (0.83)
SCHEMBL7296108 0.90 TDP1 (0.82)
SCHEMBL7296555 0.90
SCHEMBL1050014 0.88 TDP1 (0.78)
SCHEMBL2285048 0.88 TDP1 (0.78)
SCHEMBL8596237 0.87 TDP1 (0.76)
SCHEMBL8596242 0.87 TDP1 (0.76)
SCHEMBL18028783 0.84 TDP1 (0.72)
SCHEMBL7350548 0.84 TDP1 (0.72)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090104116-A1 COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF JERINI AG (DE) 2009-04-23 US claimed
US-20080306067-A1 Modulators of Chemokine Receptor Activity WEIGAND KLAUS 2008-12-11 US claimed
EP-1979342-A1 COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF Jerini AG (DE) 2008-10-15 EP claimed
EP-1943235-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Novartis AG (CH) 2008-07-16 EP claimed
WO-2007088041-A1 COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF JERINI AG (DE) 2007-08-09 WO claimed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO claimed
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
EP-4655299-A1 NEW COMPOUNDS FOR TREATING STAPHYLOCOCCUS INFECTIONS Ab2 Therapeutics, S. L. (ES) 2025-12-03 EP disclosed
EP-4171563-B1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-08-06 EP disclosed
US-20250092019-A1 TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-03-20 US disclosed
WO-2024156895-A1 NEW COMPOUNDS FOR TREATING STAPHYLOCOCCUS INFECTIONS ABAC Therapeutics, S.L. (ES) 2024-08-02 WO disclosed
EP-4406952-A1 NEW COMPOUNDS FOR TREATING STAPHYLOCOCCUS INFECTIONS ABAC THERAPEUTICS, S.L. (ES) 2024-07-31 EP disclosed
US-11884652-B2 Tetrazole derivatives as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-30 US disclosed
WO-2007088041-A1 COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF JERINI AG (DE) 2007-08-09 WO disclosed
US-20070179127-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-02 US disclosed
WO-2007048771-A1 ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY NOVARTIS AG (CH) 2007-05-03 WO disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-0389282-B1 Xanthinederivatives, process for their preparation and their pharmaceutical use SMITHKLINE BEECHAM PHARMA GMBH (DE) 2002-02-20 EP disclosed
EP-0386683-A2 Xanthine derivatives having bronchodilating activity, a process for the preparation thereof and pharmaceutical compositions containing them POLI INDUSTRIA CHIMICA S.p.A. (IT) 1990-09-12 EP disclosed
US-3984568-A Fungicidal cyclopropyl substituted 2-cyanoacetamide derivatives E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-10-05 US disclosed